In BriefSpinal cord injury is among the most devastating neurological conditions affecting humans. The authors assessed the therapeutic efficacy of subcutaneous recombinant granulocyte colony-stimulating factor as an adjunct to classic surgical and rehabilitative treatments for subacute traumatic spinal cord injuries. This safe and noninvasive treatment may be helpful for better care and satisfaction of patients with this devastating condition throughout the world.
Keywords: AIS = ASIA Impairment Scale; ASIA = American Spinal Injury Association; BASIR = Brain and Spinal cord Injury Research; CBC = complete blood count; CONSORT = Consolidated Standards of Reporting Trials; G-CSF = granulocyte colony-stimulating factor; IANR-SCIFRS = International Association of Neurorestoratology Spinal Cord Injury Functional Rating Scale; ISNCSCI = International Standards for Neurological Classification of Spinal Cord Injury; MAS = Modified Ashworth Scale; MPSS = methylprednisolone sodium succinate; SCIM-III = Spinal Cord Independence Measure version III; TSCI = traumatic spinal cord injury; TUMS = Tehran University of Medical Sciences; VAS = visual analog scale; WBC = white blood cell; clinical trial; granulocyte colony-stimulating factor; neurological improvement; spinal cord injury.